Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Deals Policy / Regulatory

Sinopharm Expands Partnership with Guizhou Government to Boost Health Industry

Fineline Cube Jun 26, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strengthened partnership with the...

Company Deals

Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development

Fineline Cube Jun 26, 2023

China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the...

Company Drug

CANbridge Pharmaceuticals Reports Positive Phase Ib Results for Omoprubart in PNH Treatment

Fineline Cube Jun 26, 2023

China-based rare disease firm CANbridge Pharmaceuticals Inc., (HKG: 1228) has published the preliminary results of...

Company Medical Device

Sino Medical Sciences Technology Secures FDA Thailand Approval for NC Rockstar Balloon Catheter

Fineline Cube Jun 26, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received market...

Company Drug

Haisco Pharmaceutical’s HSK31679 Receives Clinical Trial Approval for NASH Treatment

Fineline Cube Jun 26, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category...

Company Drug

NMPA Approves XZenith Biopharm’s Anaprazole for Duodenal Ulcer Treatment

Fineline Cube Jun 26, 2023

The National Medical Product Administration (NMPA) has granted marketing approval for anaprazole, a proton pump...

Company Drug

Sichuan Kelun’s SKB264 Earns Breakthrough Therapy Designation for Breast Cancer Treatment

Fineline Cube Jun 26, 2023

The Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Kelun Pharmaceutical Co.,...

Company Drug

Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023

Fineline Cube Jun 26, 2023

China’s Brii Biosciences (HKG: 2137) announced that its strategic partners, Vir Biotechnology Inc., (NASDAQ: VIR)...

Company Deals

Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs

Fineline Cube Jun 26, 2023

Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition...

Company Deals Drug

Innovent Biologics and RemeGen Partner on Clinical Study for PD-1 Inhibitor and ADC Drugs

Fineline Cube Jun 26, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has entered into a clinical study and supply cooperation...

Company Drug

Sino-Cuban JV Biotech Pharmaceutical Receives NMPA Approval for Nimotuzumab in Pancreatic Cancer

Fineline Cube Jun 25, 2023

Sino-Cuban joint venture (JV) Biotech Pharmaceutical Limited (BPL) announced last week that it has received...

Company Drug

Sarepta Therapeutics’ Elevidys Receives FDA Accelerated Approval for Duchenne Muscular Dystrophy

Fineline Cube Jun 25, 2023

US-based Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has announced that the U.S. Food and Drug Administration...

Company Drug

S-Evans Biosciences Receives NMPA Tacit Approval for Stem Cell Therapy in ARDS

Fineline Cube Jun 25, 2023

S-Evans Biosciences, a stem cell specialist based in Hangzhou, has obtained tacit clinical trial approval...

Company Deals

Kite Pharma’s Yescarta Marketing Rights Transferred to Gilead Sciences K.K. in Japan

Fineline Cube Jun 25, 2023

US immunotherapy specialist Kite Pharma, Inc. has announced that the Marketing Authorization for Yescarta (axicabtagene...

Company Drug

Hopstem Biotechnology’s hNPC01 Receives Tacit Approval for Stroke Sequelae Treatment from CDE

Fineline Cube Jun 25, 2023

Hopstem Biotechnology Co., Ltd, a neural stem cell specialist founded by neuroscientists and stem-cell biologists...

Company Deals

Edding Pharma Aims for Fifth IPO Attempt on Hong Kong Stock Exchange

Fineline Cube Jun 25, 2023

China-based Edding Pharma is gearing up for its fifth attempt to hold an initial public...

Drug Policy / Regulatory

CDE Releases Guidelines for Clinical Trials of Stem Cell Therapies and Derived Products

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a set of “Guidelines for Clinical Trial...

Company Drug

Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide

Fineline Cube Jun 25, 2023

Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...

Drug Policy / Regulatory

CDE Releases Draft Guidelines for Antibody Drug Conjugate Research and Evaluation

Fineline Cube Jun 25, 2023

The Center for Drug Evaluation (CDE) has released a draft set of “Guiding Principles for...

Company Deals

Aureka Biotechnologies Secures $10 Million in Seed Funding for AI-Driven Biotechnology

Fineline Cube Jun 25, 2023

Aureka Biotechnologies Inc., a California-based artificial intelligence (AI)-empowered biotech company, has successfully raised USD 10...

Posts pagination

1 … 564 565 566 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.